Skip to content

Axsome has development plans on AXS-05 for Alzheimer’s agitation

August 31, 2020

Axsome Therapeutics (AXSM -2.7%) confirms pivotal development status and plan for AXS-05 in the treatment of Alzheimer’s disease (AD) agitation following a successful Breakthrough Therapy meeting with the FDA.

AXS-05 (dextromethorphan/bupropion modulated delivery tablet) is an oral, investigational NMDA receptor antagonist and sigma-1 receptor agonist. There is currently no approved treatment for AD agitation.

Results of the meeting confirm the pivotal status of the previously completed positive ADVANCE-1 trial, and the establishment of the superiority of AXS-05 over its components.

Consequently, only one additional Phase 3 efficacy trial will be needed to support the NDA filing for approval of AXS-05 in this indication, and only a placebo control will be required.

Axsome is on track to initiate this efficacy trial in Q4. The Company also plans to launch an open-label safety extension trial of AXS-05 in AD agitation patients in Q4 to supplement the existing AXS-05 long-term safety database.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: